| Browse All

Surrozen, Inc. (SRZNW)

South San Francisco, United States | NasdaqCM
0.02 USD +0.00 (1.596%) ⇧ (April 17, 2026, 12:42 p.m. EDT)

Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 12:57 a.m. EDT

High-risk speculative asset with deteriorating fundamentals, negative cash flow, and zero dividend yield; weak forecasting signals and 52-week lows suggest strong sell or avoid signal.

None
Attribute Value
Revenue per Share 0.465
Beta 0.52
Previous Name Consonance-HFW Acquisition Corp.
Website https://www.surrozen.com

Info Dump

Attribute Value
Address1 171 Oyster Point Boulevard
Address2 Suite 400
Ask 0.0
Ask Size 0
Beta 0.517
Bid 0.0
Bid Size 0
Book Value -19.209
City South San Francisco
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.0191
Current Ratio 9.22
Custom Price Alert Confidence HIGH
Day High 0.0191
Day Low 0.0188
Display Name Surrozen
Ebitda -41,555,000
Ebitda Margins 0.0
Eps Trailing Twelve Months -5.695
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Two Week High 0.0191
Fifty Two Week High Change 0.0
Fifty Two Week High Change Percent 0.0
Fifty Two Week Low 0.0188
Fifty Two Week Low Change 0.0002999995
Fifty Two Week Low Change Percent 0.01595742
Fifty Two Week Range 0.0188 - 0.0191
Financial Currency USD
First Trade Date Milliseconds 1,772,807,400,000
Float Shares 5,421,151
Free Cashflow -16,856,500
Full Exchange Name NasdaqCM
Full Time Employees 44
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -25,888,000
Has Pre Post Market Data 1
Industry
Industry Key
Ipo Expected Date 2,021-08-12
Language en-US
Long Business Summary Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Long Name Surrozen, Inc.
Market us_market
Market State CLOSED
Max Age 86,400
Message Board Id finmb_401948183
Name Change Date 2,026-04-19
Net Income To Common -242,026,000
Open 0.009
Operating Cashflow -30,244,000
Operating Margins -23.9375
Phone 650 489 9000
Prev Name Consonance-HFW Acquisition Corp.
Previous Close 0.0188
Price Hint 4
Price To Book -0.0009943255
Profit Margins 0.0
Quick Ratio 9.008
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0002999995
Regular Market Change Percent 1.5957421
Regular Market Day High 0.0191
Regular Market Day Low 0.0188
Regular Market Day Range 0.0188 - 0.0191
Regular Market Open 0.009
Regular Market Previous Close 0.0188
Regular Market Price 0.0191
Regular Market Time 1,776,444,164
Regular Market Volume 2,992
Return On Assets -0.35746
Revenue Growth -0.194
Revenue Per Share 0.465
Sand P52 Week Change 0.38150132
Sector
Sector Key
Short Name Surrozen, Inc. Warrant
Source Interval 15
State CA
Symbol SRZNW
Total Cash 89,245,000
Total Cash Per Share 7.769
Total Debt 6,639,000
Total Revenue 3,477,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -5.695
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 2,992
Website https://www.surrozen.com
Zip 94,080